Episode Details
Back to Episodes
Daily Roundup | Celcuity Revtorpyk Approved: The Label Line That Makes It a Takeout Target
Published 1 week, 2 days ago
Description
Celcuity's Revtorpyk (gedatolisib) wins FDA approval in HR+/HER2- breast cancer on a 0.24 hazard ratio — and the stock jumped to $111. Plus AstraZeneca's up-to-$1.5B Zegfrovy license from spinoff Dizal, Biogen's diranersen tau data at AAIC, the NextCure–Avere oral IL-23 merger, and Roche scrapping two Ionis Huntington's programs.
Visit us at thepharmacloseout.com.